CD274 and breast cancer: Despite the reports that monoclonal antibodies that directly inhibit PD-1 and PD-L1 have been a successful treatment options for advanced melanoma, non-small cell lung carcinoma (NSCLC), and some patients with high mutational burden like HNPCC colorectal cancer, limited success rate was noted in breast cancer clinical trials (53).